gray semaglutide Lowers Risk of Major Kidney Outcomes, Cardiovascular Events, Death in Patients With Diabetes and CKD Compounded “Semaglutide” vs Wegovy® (semaglutide)

These delays highlight the structural barriers that can slow adoption in populations with higher rates of comorbidities

As these medications reduce overall energy intake, individuals are consuming fewer calories with estimates placing this reduction between 16 and 39%, or about 700 calories per day on average (Christensen et al., 2024)

This could be a reflection of the low perception of CV risk in people with T2D observed among this group of physicians [3]

A biosimilar is a medication that is made from the same sources and has the same risks and benefits, but it often costs less than the original

provider or insurance

Burak Altintas, MD, an orthopedist with UTMB, who was not involved in this study, further highlighted the following limitations of the research: The limitations include retrospective design and likely residual confounding despite matching as fracture risk is influenced by many variables that are not reported [] Further, the comparison group is heterogeneous, combining another GLP-1 receptor agonist (dulaglutide) with two mechanistically different weight-loss medications